title: Patient willingness to take teriparatide.
abstract: OBJECTIVE
  Teriparatide [rhPTH (1-34)] is an effective treatment for osteoporosis administered by daily subcutaneous injection. The objective of this study was to determine how much benefit women expect teriparatide to confer before agreeing to perform daily injections.
  
  
  METHODS
  We recruited postmenopausal women who had recently undergone bone densitometry and were found to have either a T-score less than -2.5 at the hip or spine and/or had a fracture index (FI) of > or =6. Participants completed an adaptive conjoint analysis questionnaire to determine their treatment preferences.
  
  
  RESULTS
  The study sample included 185 women, mean age 71 (range 46-90). An increasing number of subjects preferred rhPTH (1-34) as the efficacy of teriparatide increased, but most women demanded efficacy advantages greater than those demonstrated in clinical studies. We found no association between absolute fracture risk and preference for rhPTH (1-34); however, subjects with an excessively high perceived risk of future fracture were more likely to accept daily subcutaneous injections compared to subjects with a lower perceived risk of future fracture (40% versus 15%, p = 0.001).
  
  
  CONCLUSIONS
  Our results suggest that most women demand benefits far greater than those conferred by rhPTH (1-34) in order to administer daily subcutaneous injections to decrease their future risk of fractures.
  
  
  CONCLUSIONS
  Given the poor adherence for treatment of osteoporosis, and the choices older adults must make when paying for medications, development of novel treatment approaches should be based on older adults' treatment preferences.
authors.affiliation: VA Connecticut Healthcare System, USA. liana.fraenkel@yale.edu
authors.forename: Liana
authors.initials: L
authors.lastname: Fraenkel
authors.forename: Barbara
authors.initials: B
authors.lastname: Gulanski
authors.forename: Dick
authors.initials: D
authors.lastname: Wittink
mesh_terms: D015502:Absorptiometry, Photon; D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002755:Choice Behavior; D003237:Connecticut; D004334:Drug Administration Schedule; D005260:Female; D050723:Fractures, Bone / Q000209:etiology; D007722:Health Knowledge, Attitudes, Practice; D006301:Health Services Needs and Demand; D006801:Humans; D007279:Injections, Subcutaneous; D008875:Middle Aged; D015999:Multivariate Analysis; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000175:diagnosis / Q000517:prevention & control / Q000523:psychology*; D010342:Patient Acceptance of Health Care / Q000523:psychology*; D017698:Postmenopause / Q000523:psychology*; D018570:Risk Assessment; D012959:Socioeconomic Factors; D011795:Surveys and Questionnaires; D019379:Teriparatide / Q000627:therapeutic use*; D014930:Women / Q000193:education / Q000523:psychology*
chemical_list: D050071:Bone Density Conservation Agents; D019379:Teriparatide